Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Blood transfusions may save lives, but the Blood Transfusion Diagnostics Market ensures its safety and efficacy. The market is crucial because of this. This industry includes several diagnostic instruments and equipment that screen and match blood products to recipients. Thus, problems are decreased and patient outcomes improved.
Several reasons are driving worldwide blood transfusion demand. Surgery, trauma, and medical illnesses are among these causes. Demand is driving the Blood Transfusion Diagnostics Market, highlighting the need for precise, effective diagnostic solutions.
Continuous blood typing technology development is a notable trend in the business. Molecular approaches like PCR and nucleic acid testing are replacing older ones. Both methods are molecular. These approaches provide more accurate and faster results. These modifications increase blood compatibility and lessen transfusion problems.
Because blood transfusion safety is paramount, the industry prioritizes screening and testing. Modern diagnostic equipment can identify infectious agents, guaranteeing that given blood is clear of viruses, germs, and other disorders.
Automation is becoming increasingly prevalent in blood transfusion diagnostics, simplifying processes and improving workflow. Automated blood grouping, crossmatching, and infectious disease screening minimize human error, increase throughput, and improve blood transfusion safety and dependability.
Blood transfusion diagnosis requires more POCT. POCT technology enables speedy, on-site decision-making in crises and distant healthcare institutions. Decentralised testing in healthcare improves accessibility and efficiency.
Stronger healthcare infrastructure and more awareness of blood transfusions may have led to more blood transfusion services in emerging countries. Because of this development, reliable diagnostic approaches that ensure blood product safety are needed. Market participants are carefully positioning themselves to profit on these new prospects.
The Blood Transfusion Diagnostics Market is growing rapidly due to information technology. Data management, traceability, and reporting in blood transfusion services have improved due to digitization and IT technologies. This connection improves transfusion diagnosis and simplifies regulatory compliance.
Diagnostic firms, blood banks, and healthcare institutions are collaborating and signing agreements. This tendency is spreading. These alliances aim to combine resources, networks, and experience to provide comprehensive and coordinated solutions. These alliances help expand market share and produce cutting-edge diagnoses.
This sector is distinguished by its focus on regulatory compliance and industry homogeneity. Blood transfusion diagnostics are safe and reliable if done according to strict regulatory criteria. Market actors are investing heavily in R&D to meet and surpass regulatory requirements.
Blood Transfusion Diagnostics Market Highlights:
Blood Transfusion Diagnostics Market Overview
Blood Transfusion Diagnostics Market Size was valued at USD 4.75 Billion in 2023. The Global Blood Transfusion Diagnostics industry is projected to grow from USD 5.03 Billion in 2024 to USD 7.89 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period (2024 - 2032).
Blood transfusion diagnostics is the intravenous transfer of blood or blood products. Blood transfusions can be used to replace blood components that have been lost. The most common blood components transfused include red blood cells, white blood cells, platelets, clotting factors, and plasma. During an emergency or a serious case of massive blood loss, these blood components are crucial to laboratories and hospitals. When hemoglobin levels fall below 100g/L, RBC transfusion is required. Before being transfused, blood from a donor must be checked for a variety of infectious diseases.
Blood transfusion demand is being driven by the rising prevalence of chronic and infectious diseases such as severe anemia, cancer, hemophilia, kidney disease, liver disease, severe infection, sickle cell disease, and thrombocytopenia, as well as the introduction of technologically advanced products. As a result, blood transfusion diagnostics play a vital role in preventing infection in both the recipient and the healthcare workers. The expansion of this market is fueled by rising infectious disease prevalence, an increase in the number of blood transfusion procedures, the need for screened blood products, and increased campaigning or awareness campaigns. The demand for blood and blood products outnumbers the supply, adding to the Blood Transfusion Diagnostics market's expansion.
November 2023
Versiti, an organization renowned for its pioneering efforts in blood health innovation, declared today the procurement of Pearl Pathways, a favored collaborator and trusted advisor in the life sciences industry, to facilitate the development of innovative and expedited products.
Pearl Pathways, headquartered in Indianapolis, is a comprehensive life science consulting firm that specializes in delivering specialized CRO services, regulatory affairs, and quality compliance. An additional AHRPP-accredited, independent IRB oversees all facets of human research at Pearl. With regard to life science service providers and biopharmaceutical, medical device, and diagnostic companies, the organization provides comprehensive support in terms of clinical, regulatory, and quality compliance requirements.
"Pearl Pathways brings deep expertise in life science product development, which ultimately leads to getting life-saving devices, diagnostics, and therapeutics to patients faster," said Versiti President and Chief Executive Officer Chris Miskel. "By engaging in this strategic collaboration, Versiti Clinical Trials enhances the range and variety of its research-based solutions while also fortifying its spectrum of capabilities to facilitate earlier disease cures."
By enabling Versiti to assist clinical trials sponsors earlier and further along the development pathway, while continuing to provide services until regulatory approval and commercialization, Pearl Pathways expands the organization's scope.
This transaction further enhances the functionalities established by Versiti's Diagnostic Laboratories. It transpires subsequent to the organization's procurement of Quantigen, a specialized laboratory situated in Fishers, Indiana, and Cenetron Central Laboratories and Salus IRB, both based in Texas, earlier this year.
"The Pearl Pathways staff is ecstatic to announce their entry into Versiti." With the aim of enhancing patient care, Versiti has supported fundamental and translational research for decades. "Pearl and Versiti will work together to accelerate the development of the next generation of therapies and devices," stated Gretchen Bowker, founder of Pearl Pathways.
More than 2,300 individuals are employed by Versiti, which has offices in Wisconsin, Illinois, Indiana, Michigan, Ohio, and Texas, in addition to its Milwaukee headquarters.
Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.
- To provide detailed analysis of the market structure along with forecast for the next seven years of the various segments and sub-segments of the Blood Transfusion Diagnostics market.
- To provide insights about factors affecting the market growth.
- To analyze the Blood Transfusion Diagnostics market based on various factors- Price Analysis, Supply Chain Analysis, Porters’ Five Force Analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies - Americas, Europe, Asia Pacific and Middle East & Africa and their countries.
- To provide country level analysis of the market with respect to the current market size and future prospective.
- To provide country level analysis of the market for segments by product, by technology, by end and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Blood Transfusion Diagnostics Market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Blood Transfusion Diagnostics market.
Key Players
- Grifols (Spain)
- Thermo Fisher Scientific, Inc. (U.S.)
- Roche Diagnostics (Switzerland)
- bioMérieux (France)
- Bio-Rad Laboratories Inc. (U.S.)
- Immucor (U.S)
- Siemens Healthineers (Germany)
- Ortho Clinical Diagnostics Inc. (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Novartis AG (Switzerland)
- Beckman Coulter Inc. (U.S.)
- Ortho Clinical Diagnostics (U.S)
- Beckman Coulter (U.S)
- Diagast (France)
- Abbott Diagnostics (U.S)
- BAG healthcare (Germany)
- DiaSorin (Italy)
- Fujirebio (Belgium)
- Grifols (Spain)
- Quidel (U.S)
- Hologic/Gen-Probe (U.S)
- Biokit (Spain)
The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Blood Transfusion Diagnostics Market Segmentation
Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products.
On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Blood Transfusion Diagnostics Market Regional Analysis
Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.
Recent Development
Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.
Intended Audience
-
- Medical device manufactures
- Medical devices suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Academic Medical Institutes and Universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
